Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading academic institutions, pharmaceutical and biotechnology companies, patient advocacy groups and venture capitalists. Drug discovery solutions are provided in form of integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates and fee-for-service work. The Company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, fibrosis, respiratory and infectious diseases. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased and comprehensive infrastructure.Visit website
Evotec has long-term discovery alliances with partners including Bayer, CHDI, Sanofi, Genentech and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships e.g. with Sanofi in the field of diabetes as well as cancer immunotherapy, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. Moreover, Evotec is seeking to broaden its relationship with top-tier academic centres to accelerate the development of next-generation therapeutic approaches to treat or cure diseases with high unmet medical needs.
Evotec is built on integrated drug discovery know-how of over 20 years and is a leading player in the drug discovery field. The Company’s headquarters are located in Hamburg, Germany. Additional major operating sites exist in Abingdon and Macclesfield, UK; Goettingen and Munich, Germany; Toulouse, France; Verona, Italy; as well as Branford and Princeton, USA. Evotec has more than 2,100 employees worldwide.